: 10x Genomics stock falls as revenue forecast disappoints


Shares of 10x Genomics Inc. TXG, -7.74% fell in the extended session Thursday after the biotech company said it expects second-quarter revenue to come in below Wall Street expectations. 10x Genomics shares dropped 15% after hours, following a 7.7% drop in the regular session to close at $43.29. The company said it expects second-quarter revenue of $114.5 million, a decline of 1% from last year’s $115.8 million. Analysts surveyed by FactSet had estimated revenue of $127.7 million. Back in May, the company reaffirmed its full-year revenue forecast of $600 million to $630 million, while the Street expects $610.9 million.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleThe Wall Street Journal: Payments startup Stripe slashes its internal valuation by nearly 30%
Next articleU.S. stock benchmarks run risk of longest losing streak in a month


Please enter your comment!
Please enter your name here